<DOC>
	<DOCNO>NCT01105091</DOCNO>
	<brief_summary>This prospective , multi-center , open-label , randomize , Phase IV exploratory study compare safety , tolerability , pharmacokinetics , effectiveness ACT-385781A Flolan ( epoprostenol sodium ) patient pulmonary arterial hypertension naïve injectable prostanoid treatment need treatment . Approximately 30 patient 8 U.S. clinical site randomize receive either ACT-385781A Flolan ( 2:1 respectively ) 28 day treatment .</brief_summary>
	<brief_title>Epoprostenol Injection Pulmonary Arterial Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Familial Primary Pulmonary Hypertension</mesh_term>
	<mesh_term>Epoprostenol</mesh_term>
	<mesh_term>Tezosentan</mesh_term>
	<criteria>1 . Male female subject age 1865 year 2 . Patients follow type pulmonary arterial hypertension ( PAH ) belonging WHO Group I : Idiopathic ( IPAH ) Heritable ( HPAH ) Associated ( APAH ) Connective tissue diseases Drugs toxins 3 . Patients PAH modify NYHA functional class III IV time enrollment need injectable epoprostenol . 4 . Patients must injectable prostanoid treatmentnaïve either newly diagnose yet treat specific PAH therapy currently treat exist background PAH therapy one follow medication 90 day prior enrollment stable dose 30 day prior enrollment : Bosentan Ambrisentan Sildenafil Tadalafil 5 . Women childbearing potential must use reliable method contraception . 1 . Patients respiratory and/or cardiovascular distress need emergency care include i.v . epoprostenol administration vasopressive i.v . drug 2 . Known pulmonary venoocclusive disease ( PVOD ) 3 . Current use i.v . inotropic agent 4 . Tachycardia heart rate &gt; 120 beats/min 5 . Pulmonary arterial hypertension relate condition specify inclusion criterion 6 . Known hypersensitivity formulation ACT385781A excipients , Flolan excipients 7 . Use inhaled iloprost treprostinil week prior screen 8 . Cerebrovascular event ( e.g. , transient ischemic attack stroke ) within 6 month screen 9 . History myocardial infarction 10 . History leftsided heart disease , include follow : hemodynamically significant aortic mitral valve disease restrictive congestive cardiomyopathy leave ventricular ejection fraction &lt; 40 % multigated radionucleotide angiogram ( MUGA ) , angiography , echocardiography unstable angina pectoris lifethreatening cardiac arrhythmia 11 . Chronic bleed disorder 12 . Infection ( ) within past month mind investigator would contraindicate use epoprostenol 13 . Pregnancy breastfeed 14 . Participation another clinical trial , except observational ( noninterventional ) , receipt investigational product within 30 day prior randomization 15 . Any known factor disease might interfere treatment compliance , study conduct interpretation result drug alcohol dependence psychiatric disease 16 . Known concomitant lifethreatening disease PAH life expectancy &lt; 12 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>November 2012</verification_date>
	<keyword>Pulmonary Arterial Hypertension</keyword>
	<keyword>PAH</keyword>
	<keyword>EPITOME-1</keyword>
</DOC>